Navigation Links
Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
Date:3/23/2011

THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced new long-term data showing that during the fourth and fifth years of Prolia® (denosumab) treatment, postmenopausal women with osteoporosis receiving Prolia continued with further, statistically significant, year-over-year increases in lumbar spine and total hip bone mineral density (BMD), a key measurement of bone strength. The overall adverse event profile was similar for the fourth and fifth years of consecutive Prolia treatment.

The data, which were presented at the annual European Congress Osteoporosis and Osteoarthritis (ECCEO11-IOF) in Valencia, Spain, showed that treatment with Prolia, the first and only approved RANK Ligand inhibitor for the treatment of postmenopausal osteoporosis, resulted in robust BMD gains after five continuous years of treatment (13.7 percent for lumbar spine BMD and 7.0 percent for total hip BMD).  

The FREEDOM Study and the 5-Year Prolia Data The pivotal FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) study established the efficacy and safety of Prolia based on three years of data from approximately 7,800 postmenopausal women. The open-label extension of FREEDOM is evaluating the long-term (up to 10 years) efficacy and safety of Prolia in 4,550 postmenopausal women. Seventy percent of eligible women from the FREEDOM study continued enrollment in the extension study; 2,343 women continued to receive Prolia treatment, and 2,207 transitioned from placebo to Prolia.

Continued treatment with Prolia resulted in consistent year-over-year gains in BMD at the lumbar spine and total hip. In years 4 and 5 respectively, women taking Prolia experienced further 1.9 percent and 1.7 percent increases in lumbar spine BMD and further 0.7 percent and 0.6 percent increases in total hip BMD (all P<0.0001 comp
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
2. The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
3. XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
4. Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
5. Prolia™ (denosumab) Receives Best New Drug Honor at Scrip Awards
6. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
7. MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial
8. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
9. MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment in Open-Label Trial and Completion of Treatment in QT Trial for LEVADEX™ Clinical Program
10. Phase 3 Open-Label Study Comparing Tapentadol Extended Release Tablets to Oxycodone Controlled Release Tablets Published by Pain Practice
11. Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , August 29, 2014 ... participate in the inaugural Tweetchat taking place in ... Worldwide , organised by UBM Live , ... #CPhIChat is a first of its kind global ... across the supply chain, aimed to stimulate conversations ...
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces that ... in its catalogue: Needle-Free Delivery: ... http://www.reportlinker.com/p02332847/Needle-Free-Delivery-Technology-and-Market-Forecast-2014-2024.html Report ... and commercial prospects What does the future ... brand new report shows you the potential ...
(Date:8/28/2014)... DALLAS , Aug. 28, 2014 /PRNewswire-iReach/ -- ... Poland (Photo - ... " CountryFocus: Healthcare, Regulatory and Reimbursement Landscape Poland ... identifies key trends in the healthcare market and ... and healthcare infrastructure. Most importantly, the report provides ...
Breaking Medicine Technology:CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 2CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 3Needle-Free Delivery: Technology and Market Forecast 2014-2024 2Needle-Free Delivery: Technology and Market Forecast 2014-2024 3Needle-Free Delivery: Technology and Market Forecast 2014-2024 4Needle-Free Delivery: Technology and Market Forecast 2014-2024 5Needle-Free Delivery: Technology and Market Forecast 2014-2024 6Needle-Free Delivery: Technology and Market Forecast 2014-2024 7Needle-Free Delivery: Technology and Market Forecast 2014-2024 8Needle-Free Delivery: Technology and Market Forecast 2014-2024 9Needle-Free Delivery: Technology and Market Forecast 2014-2024 10Needle-Free Delivery: Technology and Market Forecast 2014-2024 11Needle-Free Delivery: Technology and Market Forecast 2014-2024 12Needle-Free Delivery: Technology and Market Forecast 2014-2024 13Needle-Free Delivery: Technology and Market Forecast 2014-2024 14Needle-Free Delivery: Technology and Market Forecast 2014-2024 15Needle-Free Delivery: Technology and Market Forecast 2014-2024 16Needle-Free Delivery: Technology and Market Forecast 2014-2024 17Needle-Free Delivery: Technology and Market Forecast 2014-2024 18Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5
... AMSTERDAM, May 30 Amsterdam Molecular,Therapeutics (Euronext: AMT), ... therapy,today announced that positive interim data from its ... were presented by the,Principal Investigator, professor Daniel Gaudet, ... in Boston on May 29th. These data confirm ...
... CHELMSFORD, Mass., May 29 Magellan Biosciences, ... feature,automated systems and assays designed to streamline ... at the 108th meeting of the,American Society ... and Dynex Technologies, will share booth 743 ...
Cached Medicine Technology:AMT Announces Positive Interim Clinical Data on its Lead Product AMT-011 2AMT Announces Positive Interim Clinical Data on its Lead Product AMT-011 3Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743 2Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743 3
(Date:8/29/2014)... HealthDay Reporter THURSDAY, Aug. ... American babies are getting the vaccines they need to ... Thursday. More than 90 percent of children are ... (MMR); polio; hepatitis B and chickenpox (varicella), according to ... "Nationally, vaccination among children 19 to 35 months of ...
(Date:8/29/2014)... Floors of hospitals and other medical facilities tend ... patients are relegated to lying down or sitting due ... Two inventors from Perrysburg, Ohio, have designed the patent-pending ... special pair of socks helps prevent slips and falls ... relegated to beds or chairs from standing and walking ...
(Date:8/29/2014)... -- Selling cigarettes in plain packages doesn,t increase the ... sales in small stores, according to new research from ... industry when it tried to prevent Australia from becoming ... packaging for tobacco products in 2012. Similar legislation is ... Researchers surveyed nearly 2,000 adult smokers in Australia ...
(Date:8/29/2014)... Vancouver, BC (PRWEB) August 29, 2014 ... announced that the company will now be selling purse-sized ... in such a way that they can be carried ... are they portable, the purse-sized range at Honey Gifts ... A long battery life and rechargeable batteries are common ...
(Date:8/29/2014)... CA (PRWEB) August 29, 2014 Evolutions ... Santa Barbara in the Santa Barbara News-Press Readers’ Choice ... won the Readers’ Choice poll as Best Medical Spa. ... 2014 reads the following about Evolutions Medical Spa recognition: ... but it is recognized as a top-notch, cutting-edge medical ...
Breaking Medicine News(10 mins):Health News:Most U.S. Babies Get Their Vaccines: CDC 2Health News:Most U.S. Babies Get Their Vaccines: CDC 3Health News:Study Counters Critics of Plainer Cigarette Packaging 2Health News:Honey Gifts Now Provides Purse Sized Adult Toys in Vancouver 2Health News:Evolutions Named Best Medical Spa in Santa Barbara by Santa Barbara News Press 2Health News:Evolutions Named Best Medical Spa in Santa Barbara by Santa Barbara News Press 3
... A team of international health experts issues a bold call ... They appeal to fund the salaries of health workers or ... diseases are made available in poor countries but there are ... from the inside of the Global Fund," say Gorik Ooms ...
... scarcity has become a universal problem. With a view ... taken up in the country.// ,In a press ... annual rainfall in India is about 1170 mm. However, ... ,The release further said that there had been ...
... of the central nervous system [CNS] in animal evolution ... evolved// from the same ancestor, but their CNSs are ... their lineages had split during evolution. Researchers from the ... that the vertebrate nervous system is probably much older ...
... violence, noise, poor housing or other chronic risk factors ... tissues than other young people. ,However, when ... these negative physiological changes, reports a new study from ... that the cardiovascular systems of youths who are exposed ...
... no monthly bleeding in women or menstruation may come as welcome ... believe it to be the symbol of fertility and would not ... ,This has created a major uproar in the health world ... new pill called Lybrel. This pill is designed to eliminate periods ...
... effective way to fight leukemia might be to knock out ... new study// shows. ,The findings suggest that a ... own be an effective therapy. ,But such a ... offer an effective one-two punch against drug-resistant forms of chronic ...
Cached Medicine News:Health News:Health Expert’s Appeal to Global Fund to Fight HIV, TB and Malari 2Health News:Stress on Storage and Conservation of Rain Water by Govt of India 2Health News:The Origin of the Brain Lies in a Worm 2Health News:Family Turmoil and Violence Results in Stress-induced Physical Problems in Young, Cornell Psychologist Finds 2Health News:Period Eliminating Pills 2Health News:Knocking Out Survival Protein Could Aid Leukemia Treatment 2
Ergotec Vetriretinal Instrument System. Extra fine angled tips (3 mm). 20 gauge shaft tapering to 23 gauge, 10 mm from tip. Overall length from rear rotation knob to tip....
Ergotec Vetriretinal Instrument System. Reverse action jaws. 0.4 mm cupped tips....
Ergotec Vetriretinal Instrument System. Ultra-fine 0.8 mm tips. Angled 40 degrees. 20 gauge shaft tapers to 23 gauge....
Ultra-fine pick shape tips for grasping and manipulating membranes. Stationary distal jaw with black finish for reduced glare....
Medicine Products: